Early Pregnancy Obesity Linked to Adverse Pregnancy Outcomes
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 16, 2023 -- Early pregnancy obesity is associated with a higher incidence of postpartum hypertension, hyperlipidemia, and diabetes, according to a study published online Oct. 10 in Circulation Research.
Sadiya S. Khan, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the correlation between body mass index and adverse pregnancy outcomes (APOs), including hypertensive disorders of pregnancy, preterm birth, small-for-gestational-age birth, and gestational diabetes, and postpartum cardiovascular disease (CVD) risk factors in a sample of adults from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-To-Be Heart Health Study, enrolled in their first trimester. A total of 4,216 participants were enrolled and had a follow-up visit at 3.7 years postpartum.
The researchers found that hypertensive disorders of pregnancy, preterm birth, small-for-gestational-age birth, and gestational diabetes occurred in 15, 8, 11, and 4 percent of participants, respectively. Compared with normal body mass index, early pregnancy obesity was associated with an increased incidence of postpartum hypertension, hyperlipidemia, and diabetes, even after adjustment for baseline CVD risk factor levels. Higher incidence rates of postpartum hypertension and hyperlipidemia were seen in association with APOs. A small proportion of the association between obesity and incident hypertension was mediated by hypertensive disorders of pregnancy (13 percent), which did not mediate associations with incident hyperlipidemia or diabetes.
"This contributes to the growing evidence base that APOs largely represent a marker of preexisting CVD risk that is unmasked during pregnancy and suggests growing emphasis on early pregnancy or prepregnancy interventions before an APO occurs," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.